Translationally, agonistic antibodies to BTN2A1 can amplify this circuit in vitro and in vivo, promote forms of immunogenic tumor cell death and inflame otherwise ‘cold’ tumors, thereby complementing PD-1/PD-L1 blockade [66]. Here, PDCD1 is linked to neoplasm.